切换至 "中华医学电子期刊资源库"
高级检索
中华移植杂志(电子版)

中华移植杂志(电子版) ›› 2018, Vol. 12 ›› Issue (02) : 91 -96. doi: 10.3877/cma.j.issn.1674-3903.2018.02.010

所属专题： 文献；

综述

供者NK细胞及其嵌合状态在异基因造血干细胞移植中的研究进展
杨芳1, 盛立霞1, 欧阳桂芳1,†()   
  1. 1. 315000　宁波大学医学院附属宁波市第一医院血液科
  • 收稿日期:2018-04-08 出版日期:2018-05-25
  • 通信作者: 欧阳桂芳
  • 基金资助:
    国家自然科学基金(81401321)

Research progress of donor NK cells and chimerism in allogeneic hematopoietic stem cell transplantation

Fang Yang1, Lixia Sheng1, Guifang Ouyang1,†()   

  1. 1. Department of Hematology, Ningbo Municipal First Hospital Affiliated to Ningbo University Medical School, Ningbo 315000, China
  • Received:2018-04-08 Published:2018-05-25
  • Corresponding author: Guifang Ouyang
  • About author:
    Corresponding author: Ouyang Guifang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨芳, 盛立霞, 欧阳桂芳. 供者NK细胞及其嵌合状态在异基因造血干细胞移植中的研究进展[J]. 中华移植杂志(电子版), 2018, 12(02): 91-96.

Fang Yang, Lixia Sheng, Guifang Ouyang. Research progress of donor NK cells and chimerism in allogeneic hematopoietic stem cell transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(02): 91-96.

目前，异基因造血干细胞移植(allo-HSCT)已广泛应用于造血系统疾病的治疗，但移植术后也存在一系列并发症。NK细胞的运用为改善allo-HSCT受者预后带来希望，供者来源NK细胞通过其细胞膜上的杀伤细胞免疫球蛋白样受体与其配体错配发挥同种异体反应，该过程具有保留移植物抗白血病和减少移植物抗宿主病双重效应。NK细胞是allo-HSCT后受者体内最早重建的免疫细胞群，因此移植后供、受者NK细胞嵌合状态评估对预测疾病预后及指导干预治疗具有重要意义。基于NK细胞嵌合状态的供者NK细胞输注免疫干预疗法可改善疾病预后，在血液系统疾病治疗中表现出良好的应用前景。本文就近年来供者NK细胞及其嵌合状态在allo-HSCT中的研究进展作一综述。

关键词: 异基因造血干细胞移植, NK细胞, 同种异体反应, 嵌合状态, 移植物抗宿主病, 移植物排斥反应

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been widely used for the treatment of hematopoietic diseases, nonetheless, major challenges persist, including a series of complications. The application of natural killer (NK) cells brings hope for improving the prognosis of patients after allo-HSCT. Killer cell immunoglobulin-like receptors (KIR) located on cytomembrane of donor NK cells and KIR-ligands mismatch plays a role in promoting the alloreactivity of NK cells, which maintains graft versus leukemia effects while reducing graft versus host disease. NK cells is the first immune cell subset to recover after allo-HSCT, so the monitoring of NK cells chimerism plays an significant role in predicting the prognosis of diseases and the intervention treatment. Furthermore, NK cells infusion based on chimerism is likely to improve the prognosis, which shows a broad application prospect in hematopoietic diseases. This article is to review the research progress of aforementioned aspects.

Key words: Allogeneic hematopoietic stem cell transplantation, Natural killer cell, Alloreactivity, Chimerism, Graft versus host disease, Graft rejection
1
Servais S,Beguin Y,Baron F. Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation[J]. Expert Opin Emerg Drugs, 2013, 18(2): 173-192.
2
Olson JA,Leveson-Gower DB,Gill S, et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects[J]. Blood, 2010, 115(21): 4293-4301.
3
Montaldo E,Del Zotto G,Della Chiesa M, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function[J]. Cytometry A, 2013, 83(8): 702-713.
4
Pietra G,Vitale C,Pende D, et al. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias[J]. Cancer Immunol Immunother, 2016, 65(4): 465-476.
5
万露露,张斌,胡亮钉. 自然杀伤细胞预防急性移植物抗宿主病相关研究进展[J]. 中国实用内科杂志，2015, 35(11): 957-960.
6
Davies JOJ,Stringaris K,Barrett AJ, et al. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease[J]. Cytotherapy, 2014, 16(11): 1453-1466.
7
王平忠,于海涛,蒋伟，等. 自然杀伤细胞受体介导抗病毒免疫的分子机制[J]. 细胞与分子免疫学杂志，2013，29(4): 441-443.
8
Benjamin JE,Gill S,Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation[J]. Curr Opin Oncol, 2010，22(2): 130-137.
9
Willemze R,Ruggeri A,Purtill D, et al. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation[J]. Best Pract Res Clin Haematol, 2010, 23(2): 283-290.
10
Minculescu L,Marquart HV,Friis LS, et al. Early NK cell reconstitution predicts overall survival in T-cell replete allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(12): 2187-2193.
11
Cooley S,Parham P,Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation[J]. Blood, 2018，131(10): 1053-1062.
12
程杰,孙自敏,刘会兰，等. 急性白血病患者非血缘脐血干细胞移植后NK细胞及其表面受体的早期重建[J]. 中国实验血液学杂志，2009, 17(2): 426-430.
13
Ullrich E,Salzmann-Manrique E,Bakhtiar S, et al. Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation[J]. Front Immunol, 2016, 7: 595.
14
Mancusi A,Ruggeri L,Urbani E, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality[J]. Blood, 2015, 125(20): 3173-3182.
15
Moretta L,Pietra G,Vacca P, et al. Human NK cells: From surface receptors to clinical applications[J]. Immunol Lett, 2016, 178: 15-19.
16
Sun JC. Re-educating natural killer cells[J]. J Exp Med, 2010, 207(10): 2049-2052.
17
Suck G,Linn YC,Tonn T. Natural killer cells for therapy of leukemia[J]. Transfus Med Hemother, 2016, 43(2): 89-95.
18
Hartman KG,Bortner JD,Falk GW, et al. Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems[J]. Exp Biol Med (Maywood), 2014，239(9): 1108-1123.
19
Blazar BR,Murphy WJ,Abedi M. Advances in graf-versus-host disease biology and therapy[J]. Nat Rev Immunol, 2012, 12(6): 443-458.
20
Ljungman P,Brand R,Hoek J, et al. Donor CMV status influences the outcome of allogeneic stem cell transplantation; a study by the European group for blood and marrow transplantation[J]. Clin Infect Dis, 2014, 59(4): 473-481.
21
Huenecke S,Cappel C,Esser R, et al. Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GVHD and viral infections[J]. Front Immunol, 2017, 8: 109.
22
Merzoni J,Ewald GM,Paz AA, et al. Quantification of mixed chimerism allows early therapeutic interventions[J]. Rev Bras Hematol Hemoter, 2014, 36(5): 369-372.
23
Baron F,Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning[J]. Leukemia, 2006, 20(10): 1690-1700.
24
万理萍,王椿,蒋瑛，等. 同种异基因造血干细胞移植后基于血细胞嵌合状态的个体化免疫治疗[J]. 诊断学理论与实践，2010, 9(1): 25-30.
25
Moscardó F,Sanz J,Senent L, et al. Impact of hematopoietic chimerism at day ＋14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies[J]. Haematologica, 2009, 94(6): 827-832.
26
洪睿敏,盛立霞,黄河，等. 各系免疫细胞嵌合状态监测在异基因造血干细胞移植后的意义[J/CD]．中华移植杂志：电子版，2017，11(4): 245-250.
27
Stikvoort A,Sundin M,Uzunel M, et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant[J]. PLoS One, 2016, 11(5): e0154737.
28
Reshef R,Hexner EO,Loren AW, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning[J]. Biol Blood Marrow Transplant, 2014, 20(11): 1758-1766.
29
苏秀华. 异基因造血干细胞移植后嵌合状态的研究进展[J]. 国际输血及血液学杂志，2015, 38(5): 406-410.
30
Childs R,Clave E,Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses[J]. Blood, 1999, 94(9): 3234-3241.
31
Breuer S,Preuner S,Fritsch G, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation[J]. Leukemia, 2012, 26(3): 509-519.
32
Baggio L,Laureano ÁM,LMDR S, et al. Natural killer cell adoptive immunotherapy: Coming of age[J]. Clin Immunol, 2017, 177: 3-11.
33
陈广华,吴德沛,孙爱宁，等. IL-2和IL-15激活供者自然杀伤细胞在异基因造血干细胞移植应用的实验研究[J]. 中华血液学杂志，2008, 29(8): 526-530.
34
Childs RW,Carlsten M. Terapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens[J]. Nat Rev Drug Discov, 2015, 14(7): 487-498.
35
Dolstra H,Roeven MWH,Spanholtz J, et al. Successful transfer of umbilical cord blood CD34＋ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients[J]. Clin Cancer Res, 2017, 23(15): 4107-4118.
36
Rubnitz JE,Inaba H,Kang G, et al. Natural killer cell therapy in children with relapsed leukemia[J]. Pediatr Blood Cancer, 2015, 62(8): 1468-1472.
37
Terwey TH,Hemmati PG,Nagy M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2014, 20(10): 1522-1529.
38
Liga M,Triantafyllou E,Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen[J]. Biol Blood Marrow Transplant, 2013, 19(1): 75-81.
39
Passweg JR,Tichelli A,Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation[J]. Leukemia, 2004, 18(11): 1835-1838.
40
Ciurea SO,Schafer JR,Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J]. Blood, 2017, 130(16): 1857-1868.
41
Locatelli F,Merli P,Rutella S. At the bedside: Innate immunity as an immunotherapy tool for hematological malignancies[J]. J Leukoc Biol, 2013, 94(6): 1141-1157.
42
Parmar S,Fernandez-Vina M,de Lima M. Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia[J]. Curr Opin Hematol, 2011, 18(2): 98-104.
43
Shaffer BC,Le Luduec JB,Forlenza C, et al. Phase Ⅱ study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(4): 705-709.
44
Vela M,Corral D,Carrasco P, et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia[J]. Cancer Letters, 2018, 422: 107-117.
[1] 陈帅, 刘文宾, 吴迪炯, 俞庆宏, 陈均法, 庄海峰, 胡致平, 武利强, 郑智茵, 沈建平, 叶宝东. 改良FAC预处理方案在不同供者类型行异基因造血干细胞移植治疗再生障碍性贫血中的疗效分析[J]. 中华危重症医学杂志(电子版), 2022, 15(04): 296-299.
[2] 孔欣, 宋宝全, 刘吟, 张剑, 仇惠英, 吴德沛. 异基因造血干细胞移植并发难治性呃逆一例[J]. 中华移植杂志(电子版), 2023, 17(04): 253-255.
[3] 陈敏, 潘田中, 孙自敏. 祛铁治疗异基因造血干细胞移植术后三系植入不良一例[J]. 中华移植杂志(电子版), 2022, 16(03): 168-171.
[4] 赵晶, 丁淑怡, 周晓瑜, 章建丽, 许丽炜, 张力晨, 严佳丽, 程琼, 刘念, 金爱云. 异基因造血干细胞移植后并发慢性移植物抗宿主病患者生活质量变化及其影响因素分析[J]. 中华移植杂志(电子版), 2022, 16(03): 153-159.
[5] 刘恒, 吴涛. 伊布替尼治疗慢性移植物抗宿主病的研究进展[J]. 中华移植杂志(电子版), 2021, 15(05): 317-320.
[6] 刘妍, 吴涛, 毛东锋, 鱼玲玲, 白海. 人类白细胞抗原全相合异基因造血干细胞移植治疗多基因突变难治性急性髓系白血病一例[J]. 中华移植杂志(电子版), 2021, 15(04): 229-231.
[7] 朱伟芳, 方红. 联合窄波紫外线治疗皮肤扁平苔藓样慢性移植物抗宿主病一例[J]. 中华移植杂志(电子版), 2021, 15(03): 169-171.
[8] 张超琅, 郭晓萍, 赵芬英, 徐晓军. 婴幼儿异基因造血干细胞移植后腹泻伴胰腺再生蛋白3α升高二例[J]. 中华移植杂志(电子版), 2021, 15(02): 116-118.
[9] 刘文慧, 吴涛, 张曦. 间充质干细胞联合血小板生成素受体激动剂在异基因造血干细胞移植后血小板恢复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 242-246.
[10] 李芸芸, 吴涛, 毛东锋, 鱼玲玲, 刘文慧. 轻型β-地中海贫血供者异基因造血干细胞移植治疗重型再生障碍性贫血1例[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 84-86.
[11] 苏春艳, 吴涛, 毛东锋, 刘文慧, 鱼玲玲, 白海. 异基因造血干细胞移植治疗急性混合细胞白血病后继发外周T细胞淋巴瘤1例[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(05): 289-292.
[12] 李翠平, 陈晓燕, 钱师宇, 林惠珠, 曾彩辉, 阳莉, 卢建溪. 不同抗凝剂保存液对脐血培养的NK细胞增殖及杀伤效应的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 572-576.
[13] 韦远, 徐西占, 梁庆丰. 免疫性眼表疾病眼表菌群的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 55-59.
[14] 杨琬芳, 许晶, 张耀方, 王青, 杨智超, 任方刚, 王宏伟. NK和NKT细胞对急性髓系白血病患者的临床影响[J]. 中华临床医师杂志(电子版), 2023, 17(9): 932-938.
[15] 赵洁, 王岚, 杨红枚, 何屹, 袁红. 异基因造血干细胞移植后并发自身免疫性溶血性贫血患者产生类抗体血清学检测方法及输血策略[J]. 中华临床医师杂志(电子版), 2022, 16(05): 452-456.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号